Eplerenone Versus PDT: Comparative Study by OCTA
OCTA in Central Serous Chorioratinopathy Treated With Oral Eplerenone or Hal-fluence Photodynamic Therapy: a Comparative Study
1 other identifier
observational
30
0 countries
N/A
Brief Summary
The study aims to analyze the changes in OCTA parameters and in choroidal thickness in patients affected by central serous chorioretinopathy treated by oral eplerenone and half-fluence photodynamic therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Oct 2015
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 30, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2017
CompletedFirst Submitted
Initial submission to the registry
October 21, 2021
CompletedFirst Posted
Study publicly available on registry
November 2, 2021
CompletedNovember 2, 2021
October 1, 2021
2.1 years
October 21, 2021
October 21, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Study of vessel density in retinal choriocapillaris networks, using OCTA, in patients underwent half fluence photodynamic therapy and oral eplerenone
To evaluate the role of optical coherence tomography angiography in predicting the changes of the vessel density of retinal and choriocapillaris vascular networks , comparing patients underwent half-fluence phodynamic therapy and patients with oral eplerenone. The vessel density are expressed as percentage
6 months
Study Arms (2)
Half fluence photodynamic therapy
Patients with central serous chorioretinopathy, treated by half-fluence photodynamic therapy
Oral Eplerenone
Patients with central serous chorioretinopathy, treated by oral eplerenone
Interventions
The patients underwent eplerenone treatment for 6 months
Half fluence photodynamic therapy for 6 months
Eligibility Criteria
The participans were older than 40 years with central serous chorioretinopathy. They did not present other ophthalmological diseases
You may qualify if:
- age older than 30 years
- diagnosis of central serous chorioretinopathy
- treatment-naïve with half-fluence photodynamic therapy or oral eplerenone
- absence of vitreoretinal and vascular retinal diseases
You may not qualify if:
- age younger than 30 years
- absence of diagnosis of central serous chorioretinopathy
- previous treatment with half-fluence photodynamic therapy or oral eplerenone
- presence of concomitant vitreoretinal and vascular retinal diseases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Gilda Cennamo
Università Federico II
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
October 21, 2021
First Posted
November 2, 2021
Study Start
October 1, 2015
Primary Completion
October 30, 2017
Study Completion
November 30, 2017
Last Updated
November 2, 2021
Record last verified: 2021-10